08
November
2023
|
07:29 AM
Europe/Amsterdam
Bayer Group:
Summary
Group sales of 10.342 billion euros (Fx & portfolio adj. minus 0.2 percent) / EBITDA before special items: 1.685 billion euros (minus 31.3 percent) / Sales stable at Crop Science and Pharmaceuticals and up slightly at Consumer Health (Fx & portfolio adj.) / Earnings lower at all divisions, especially Crop Science / Core earnings per share at 0.38 euros (minus 66.4 percent) / Net income at minus 4.569 billion euros, impacted by impairment losses at Crop Science due to interest rates / Free cash flow at 1.626 billion euros / CEO Anderson: “We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’” / Structural options remain under review
Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here